Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
e-SPACE CRM 2026
Author(s): Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira Start date: Apr 11, 2026

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
e-SPACE CRM 2026
Author(s): Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira Start date: Apr 10, 2026

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ECO 25: The RESET Trial
Author(s): Donna H Ryan Added: 11 months ago
ECO 2025 - Findings from the RESET trial show early weight loss with an oral, shape-shifting, superabsorbent, hydrogel capsule was superior to placebo and predicted long-term success in patients with overweight and obesity.Dr Donna Ryan (Pennington Biomedical, Baton Rouge, US) joins us to discuss findings from RESET (NCT04222322; Epitomee Medical). The prospective, randomised, double-blind,… View more

Cardiovascular Kidney Metabolic
ECO 24: Increasing GLP1-RA Efficacy by Targeting Non-coding RNA
Author(s): Riccardo Panella Added: 1 year ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Research Area(s) / Expertise: Job title: Medical Director and President
Dr Harold Bays is Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center, US. He has served as a Principal Investigator for over 600 clinical trials of metabolic therapeutic interventions.Dr Bays is Board Certified in Internal Medicine and Endocrinology and Metabolism, Diplomate of the American Board of Obesity Medicine, and a Diplomate of the American… View more
ACC 26: SURPASS-CVOT - Tirzepatide vs Dulaglutide in T2D
Author(s): Steven E Nissen Added: 2 weeks ago
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and… View more

Cardiovascular Kidney Metabolic

Heart Failure
HFA 24 Late-Breaker Discussion: Insights from the STEP-HFpEF
Author(s): Harriette Van Spall , Mikhail Kosiborod Added: 1 year ago
HFA 2024 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss insights from the STEP-HFpEF programme.STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Eloralintide Shows Significant Weight Loss in Phase 2 Trial
Added: 5 months ago Source:  Radcliffe CVRM
A novel, selective amylin receptor agonist, eloralintide, has demonstrated significant, dose-dependent weight loss in adults with obesity or overweight, according to the results of a 48-week phase 2 trial (NCT06230523).¹ Amylin-based therapies are an emerging class of promising medications for weight management.²This multicentre, double-blind, randomised, placebo-controlled trial was conducted… View more

Cardiovascular Kidney Metabolic
HFpEF-ABA Score Outperforms NT-proBNP in Trial Enrichment
Added: 4 months ago Source:  Radcliffe Cardiology
A new post hoc analysis of the SUMMIT trial suggests the HFpEF-ABA score is a more effective and inclusive enrichment tool than natriuretic peptide (NP) levels for clinical trials in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).¹ The findings indicate the score, which is based on age, body mass index (BMI), and history of atrial fibrillation (AF), can… View more

Imaging & Diagnostics

Cardiovascular Kidney Metabolic
Research Area(s) / Expertise: Job title: Associate Professor of Medicine and Pediatrics
Dr Fatima Cody Stanford is an obesity medicine physician scientist, educator, and policy maker at Massachusetts General Hospital and Harvard Medical School in Boston, US. She is a national and international sought after expert in obesity medicine who bridges the intersection of medicine, public health, policy, and disparities. View more